Ownership and insider activity for Adagene Inc. (ADAG): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials.
Price
| Price | $3.17 |
| Market Cap | $119M |
| Exchange | NASDAQ |
| Country | CN |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-14 | DO CUONG V | P-Purchase | 2,000 | $8K |
| 2026-08-13 | Zhu Li | A-Award | 20,000 | $60K |
| 2026-08-13 | Cheung Andy Yiu Leung | A-Award | 20,000 | $60K |
| 2026-08-13 | DO CUONG V | A-Award | 20,000 | $60K |
| 2026-08-13 | Grawunder Ulf | A-Award | 20,000 | $60K |
| 2026-08-05 | Luo Peter | P-Purchase | 279 | $1K |
| 2026-08-04 | Luo Peter | P-Purchase | 22,966 | $84K |
| 2026-03-18 | Chane-Du Mickael Yannick | |||
| 2026-03-18 | Chane-Du Mickael Yannick | |||
| 2026-03-18 | Chane-Du Mickael Yannick | 400,000 | $550K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.1M | $92.5M | $75.2M | $174.4M | $143.8M | $109.9M | $85.2M | $74.5M |
| Short-term Investments | $33.0M | $8.0M | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.4M | $2.1M | $132396 | $7.5M | $619432 | $222027 | $8309 | $17349 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $51.8M | $103.9M | $79.1M | $186.0M | $149.3M | $113.4M | $87.8M | $77.4M |
| Property, Plant & Equipment | $2.6M | $1.9M | $2.1M | $3.5M | $3.0M | $2.2M | $1.4M | $862909 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $54.4M | $105.9M | $84.3M | $189.5M | $152.4M | $115.7M | $89.3M | $78.3M |
| Accounts Payable | $558977 | $712714 | $1.8M | $3.3M | $3.7M | $3.1M | $4.2M | $2.9M |
| Short-term Debt | $2.3M | $1.0M | $5.0M | $4.5M | $13.6M | $8.4M | $17.8M | $5.0M |
| Total Current Liabilities | $10.3M | $7.2M | $16.1M | $29.8M | $55.1M | $31.5M | $38.2M | $25.2M |
| Long-term Debt | 0 | $1.5M | $3.0M | $3.0M | $14.1M | $13.5M | $417339 | $1.1M |
| Total Liabilities | $95.4M | $162.9M | $173.7M | $33.0M | $69.3M | $45.2M | $38.7M | $42.9M |
| Retained Earnings | -$46.8M | -$63.3M | -$105.7M | -$178.8M | -$258.8M | -$277.8M | -$311.2M | -$328.8M |
| Total Equity | -$41.0M | -$57.0M | -$89.4M | $156.6M | $83.1M | $70.6M | $50.5M | $35.3M |
| Total Debt | $2.3M | $2.6M | $8.0M | $7.5M | $28.0M | $22.3M | $18.5M | $6.3M |
| Net Debt | -$46.7M | -$98.0M | -$67.2M | -$166.9M | -$115.8M | -$87.6M | -$66.7M | -$68.3M |
| Working Capital | $41.5M | $96.7M | $63.0M | $156.1M | $94.2M | $82.0M | $49.6M | $52.2M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 5.02 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -4.89 |
Profitability
| Return on Equity | -29.09% |
| Return on Invested Capital | -19.62% |
| Return on Assets | -15.39% |
| Gross Margin | 94.22% |
| Operating Margin | -240.31% |
| Net Margin | -220.66% |
Related companies: ACET · CRVO · FBIO · GANX · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of ADAG: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks